Dopamine agonists in the treatment of Parkinson's disease-associated depression: a naturalistic study Save

Date Added
March 28th, 2016
PRO Number
Pro00049718
Researcher
Fredy Revilla
Keywords
Parkinsons
Summary

This is a prospective, observational, naturalistic study to assess the efficacy of dopaminergic medications in reducing depressive symptoms, as measured by validated self-rating depression scales, and compared to initiation of alternative dopaminergic therapies (e.g. L-dopa vs. DA vs. MAO-B inhibitors).

Ascertainment of a true antidepressant effect of Pramipexole, Rotigotine and/or Ropirinole (or of any of the other dopaminergic agents) would have an impact on the manner in which this disabling problem is currently addressed.

In this study, we seek to collect data on the putative antidepressant and anti-apathy effect of dopaminergic medications (L-dopa and non-ergot DA, RPN, PPX, and rotigotine [RTG]), given under naturalistic conditions to address motor impairment (not mood disorders), on PD patients, as measured by validated depression and apathy rating scales, and comparing it to changes to L-dopa and other anti-parkinsonian agents.

Institution
Greenville
Recruitment Contact
Enrique Urrea Mendoza
864-454-5076
eurreamendoza@ghs.org

Change_preferences

-- OR --

Create_login